LT3360575T - Transderminės farmacinės kompozicijos, apimančios veiksminguosius agentus - Google Patents

Transderminės farmacinės kompozicijos, apimančios veiksminguosius agentus

Info

Publication number
LT3360575T
LT3360575T LTEP18163659.8T LT18163659T LT3360575T LT 3360575 T LT3360575 T LT 3360575T LT 18163659 T LT18163659 T LT 18163659T LT 3360575 T LT3360575 T LT 3360575T
Authority
LT
Lithuania
Prior art keywords
pharmaceutical compositions
active agents
compositions containing
containing active
transdermal pharmaceutical
Prior art date
Application number
LTEP18163659.8T
Other languages
English (en)
Inventor
Valérie MASINI-ETEVE
Denis Canet
Original Assignee
Besins Healthcare Luxembourg Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Besins Healthcare Luxembourg Sarl filed Critical Besins Healthcare Luxembourg Sarl
Publication of LT3360575T publication Critical patent/LT3360575T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP18163659.8T 2009-10-27 2010-10-27 Transderminės farmacinės kompozicijos, apimančios veiksminguosius agentus LT3360575T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25524109P 2009-10-27 2009-10-27
EP09178762 2009-12-10

Publications (1)

Publication Number Publication Date
LT3360575T true LT3360575T (lt) 2023-06-12

Family

ID=42102488

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP10768983.8T LT2493508T (lt) 2009-10-27 2010-10-27 Transderminės farmacinės kompozicijos, apimančios aktyviuosius agentus
LTEP18163659.8T LT3360575T (lt) 2009-10-27 2010-10-27 Transderminės farmacinės kompozicijos, apimančios veiksminguosius agentus

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP10768983.8T LT2493508T (lt) 2009-10-27 2010-10-27 Transderminės farmacinės kompozicijos, apimančios aktyviuosius agentus

Country Status (24)

Country Link
US (2) US10080760B2 (lt)
EP (2) EP3360575B1 (lt)
JP (1) JP5727494B2 (lt)
CN (1) CN102686240B (lt)
AU (1) AU2010311523B2 (lt)
BR (1) BR112012010083B8 (lt)
CA (1) CA2778689C (lt)
CY (1) CY1120888T1 (lt)
DK (2) DK3360575T3 (lt)
ES (2) ES2685313T3 (lt)
FI (1) FI3360575T3 (lt)
HR (2) HRP20181346T1 (lt)
HU (2) HUE039200T2 (lt)
IL (1) IL219236A (lt)
LT (2) LT2493508T (lt)
PL (2) PL3360575T3 (lt)
PT (2) PT3360575T (lt)
RS (2) RS64190B1 (lt)
RU (2) RU2017131709A (lt)
SI (2) SI2493508T1 (lt)
SM (2) SMT202300143T1 (lt)
TR (1) TR201811600T4 (lt)
WO (1) WO2011051354A2 (lt)
ZA (1) ZA201202855B (lt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents
US20120004204A1 (en) * 2010-07-02 2012-01-05 Biosante Pharmaceuticals, Inc. Methods for treating sexual dysfunction while decreasing cardiovascular risk
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
EP3145489A1 (en) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natural combination hormone replacement formulations and therapies
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
EP3370178A3 (en) 2017-03-03 2018-12-19 Tata Consultancy Services Limited Method and system for in silico testing of actives on human skin
RU2751037C1 (ru) * 2020-04-03 2021-07-07 Богдан Иванович Асатуров Фармацевтическая композиция на основе аутобиокомпонентов мочи человека для трансдермального применения с лечебной или косметической целью
CN111803469B (zh) * 2020-07-15 2022-08-12 浙江海阁堂医药有限公司 一种含雌二醇透皮吸收缓释贴片及其制备方法
CN113730339B (zh) * 2021-09-17 2023-08-22 中国药科大学 一种黄体酮缓释组合物及其应用
EP4308088B1 (en) * 2021-11-08 2025-03-12 Weiyong Li Transdermal drug delivery system for delivering a drug to a patient

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1106455B (de) 1959-05-29 1961-05-10 Upjohn Co Salbengrundlage
FR2518879A1 (fr) 1981-12-30 1983-07-01 Besins Jean Medicament a base d'oestradiol pour le traitement de la pathologie menopausique
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
JPH0798935B2 (ja) 1987-11-25 1995-10-25 有限会社野々川商事 品質劣化防止剤
CA2000401C (en) 1988-10-11 1996-05-28 Masato Azuma Percutaneous pharmaceutical preparation
US5332577A (en) * 1988-12-27 1994-07-26 Dermamed Transdermal administration to humans and animals
US5232703A (en) * 1989-07-21 1993-08-03 Izhak Blank Estradiol compositions and methods for topical application
DE69007886T2 (de) * 1989-07-21 1994-11-17 Izhak Blank Östradiol enthaltende Mittel und Verfahren zur topischen Anwendung.
NZ240358A (en) 1990-10-29 1994-09-27 Alza Corp Transdermal contraceptive device comprising (as active agents) an estrogen and a gestodene together with a skin permeation enhancer
DE4227989A1 (de) 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
CZ187796A3 (en) 1993-12-27 1997-01-15 Akzo Nobel Nv Pharmaceutical preparation
CN1106259A (zh) 1994-02-05 1995-08-09 日东制药株式会社 含有作为有效成分的丙酸类非类固醇性药物的新颖消炎镇痛外用凝胶制剂
FR2732223B1 (fr) * 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
US5902603A (en) * 1995-09-14 1999-05-11 Cygnus, Inc. Polyurethane hydrogel drug reservoirs for use in transdermal drug delivery systems, and associated methods of manufacture and use
JP3081531B2 (ja) * 1996-03-22 2000-08-28 株式会社ヱビス科学研究所 手投げ消火液弾
US5762956A (en) 1996-04-24 1998-06-09 Rutgers, The State University Of New Jersey Transdermal contraceptive delivery system and process
IT1283102B1 (it) 1996-06-06 1998-04-07 Permatec Nv Composizione terapeutica per la somministrazione transdermica di un principio attivo estrogeno o progestinico o di loro miscele
RU2122396C1 (ru) 1996-07-12 1998-11-27 Валентина Александровна Андрюшина Биологически-активная добавка в косметические изделия
EP0942697A1 (en) 1996-10-30 1999-09-22 THERATECH, INC. (a Delaware Corporation) Fatty acid esters of lactic acid salts as permeation enhancers
KR100215027B1 (ko) 1997-01-27 1999-08-16 성재갑 스테로이드계 약물의 경피흡수투여용 조성물 및 이를 포함하는 경피흡수투여용 제형
JP4139860B2 (ja) 1997-11-10 2008-08-27 ストラカン インターナショナル リミティッド 浸透増強および刺激減少システム
WO1999033458A1 (en) 1997-12-25 1999-07-08 Daiichi Pharmaceutical Co., Ltd. Medicinal composition for percutaneous administration
US6582724B2 (en) * 1999-12-16 2003-06-24 Dermatrends, Inc. Dual enhancer composition for topical and transdermal drug delivery
ATE485837T1 (de) 2000-08-03 2010-11-15 Antares Pharma Ipl Ag Zusammensetzung zur transdermalen und/oder transmukosalen verabreichung von wirkstoffen, die ausreichende therapeutische spiegel garantiert
KR100416646B1 (ko) 2000-08-14 2004-02-05 구주제약주식회사 리도카인을 함유한 조루치료용 마이크로에멀젼 하이드로겔 제형의 약학 조성물
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040002482A1 (en) * 2000-08-30 2004-01-01 Dudley Robert E. Androgen pharmaceutical composition and method for treating depression
FR2814074B1 (fr) 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique
JP2002212105A (ja) 2001-01-22 2002-07-31 Lion Corp 水性皮膚外用剤組成物
US20030175329A1 (en) * 2001-10-04 2003-09-18 Cellegy Pharmaceuticals, Inc. Semisolid topical hormonal compositions and methods for treatment
US20040072810A1 (en) * 2001-11-07 2004-04-15 Besins International Belgique Pharmaceutical composition in the form of a gel or a solution based on dihydrotestosterone, process for preparing it and uses thereof
HU230920B1 (hu) * 2002-03-15 2019-03-28 Besins Healthcare Luxembourg Sarl Depresszió kezelésére szolgáló androgén gyógyászati készítmények
US6756050B2 (en) * 2002-06-28 2004-06-29 Ultra Biotech Limited Dietary supplements for improving memory
FR2848112B1 (fr) * 2002-12-10 2007-02-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
FR2851470B1 (fr) * 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
CA2519980C (en) * 2003-04-01 2012-04-10 Laboratoires Besins International Prevention and treatment of breast cancer with 4-hydroxy tamoxifen
US20070196325A1 (en) * 2004-06-07 2007-08-23 Jie Zhang Compositions and methods for dermally treating infections
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
EP1647271A1 (en) * 2004-10-14 2006-04-19 Laboratoires Besins International 4-Hydroxy tamoxifen gel formulations
EP1799201B1 (en) * 2004-10-14 2008-11-26 Laboratoires Besins International 4-hydroxy tamoxifen gel formulations
US20070082039A1 (en) * 2004-10-18 2007-04-12 Jones Gerald S Jr Synthesis of fatty alcohol esters of alpha-hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers, and topical gels for the transdermal delivery of steroids
EP1868437A4 (en) 2005-04-12 2009-08-05 Unimed Pharmaceuticals Inc METHOD FOR TREATING OR PREVENTING BONE REMOVAL OR OSTEOPOROSIS
KR20080047312A (ko) * 2005-04-25 2008-05-28 다우 파마슈티컬 사이언시즈 건선 치료를 위한 클로베타솔 분무 제형의 용도
WO2007038496A2 (en) * 2005-09-27 2007-04-05 Chemic Laboratories, Inc. Synthesis of fatty alcohol esters of hydroxy carboxylic acids, the use of the same as percutaneous permeation enhancers
EP2147674A1 (en) * 2008-07-24 2010-01-27 Besins Healthcare Transdermal pharmaceutical compositions comprising danazol
SI3202420T1 (sl) * 2008-12-11 2020-08-31 Besins Healthcare Luxembourg Sarl Transdermalni farmacevtski sestavki, ki obsegajo serm
US10080760B2 (en) 2009-10-27 2018-09-25 Besins Healthcare Luxembourg Sarl Transdermal pharmaceutical compositions comprising active agents

Also Published As

Publication number Publication date
IL219236A0 (en) 2012-06-28
JP2013508444A (ja) 2013-03-07
US20190160077A1 (en) 2019-05-30
PL3360575T3 (pl) 2023-06-05
SI2493508T1 (sl) 2018-10-30
RU2017131709A3 (lt) 2020-10-21
ES2945590T3 (es) 2023-07-04
BR112012010083A2 (pt) 2020-10-27
EP3360575B1 (en) 2023-04-19
PT3360575T (pt) 2023-05-15
CA2778689C (en) 2019-06-11
HRP20181346T1 (hr) 2018-10-19
EP3360575A1 (en) 2018-08-15
CN102686240A (zh) 2012-09-19
HRP20230482T1 (hr) 2023-10-27
CY1120888T1 (el) 2019-12-11
SI3360575T1 (sl) 2023-07-31
CA2778689A1 (en) 2011-05-05
AU2010311523B2 (en) 2013-10-17
BR112012010083B8 (pt) 2021-08-31
RU2639087C2 (ru) 2017-12-19
WO2011051354A4 (en) 2012-04-26
AU2010311523A1 (en) 2012-05-17
EP2493508A2 (en) 2012-09-05
LT2493508T (lt) 2018-10-25
RU2017131709A (ru) 2019-02-06
BR112012010083B1 (pt) 2021-05-18
WO2011051354A3 (en) 2012-03-01
PT2493508T (pt) 2018-10-09
US10080760B2 (en) 2018-09-25
ES2685313T3 (es) 2018-10-08
HUE039200T2 (hu) 2018-12-28
DK2493508T3 (en) 2018-09-03
JP5727494B2 (ja) 2015-06-03
FI3360575T3 (fi) 2023-05-05
HUE062026T2 (hu) 2023-09-28
WO2011051354A2 (en) 2011-05-05
DK3360575T3 (da) 2023-05-08
SMT202300143T1 (it) 2023-07-20
CN102686240B (zh) 2015-05-27
TR201811600T4 (tr) 2018-09-21
US20110098258A1 (en) 2011-04-28
RU2012121708A (ru) 2013-12-10
PL2493508T3 (pl) 2018-11-30
ZA201202855B (en) 2013-06-26
EP2493508B1 (en) 2018-07-18
RS64190B1 (sr) 2023-06-30
RS57596B1 (sr) 2018-11-30
IL219236A (en) 2016-02-29
SMT201800434T1 (it) 2018-11-09
US11040043B2 (en) 2021-06-22

Similar Documents

Publication Publication Date Title
LT3360575T (lt) Transderminės farmacinės kompozicijos, apimančios veiksminguosius agentus
SMT201700095B (is) Composizioni farmaceutiche per inalazione
DK3097925T3 (da) Farmaceutisk sammensætning
EP2240022A4 (en) PHARMACEUTICAL COMPOSITIONS
BRPI1004940A2 (pt) composição farmacêutica
DK3175711T3 (da) Parasitiske sammensætninger indeholdende multiple aktivstoffer, fremgangsmåder og anvendelser deraf
DK4374878T3 (da) Farmaceutisk sammensætning, der omfatter carbetocin
EP2373681A4 (en) PHARMACEUTICAL COMPOSITIONS
SMT201400069B (it) Formulazione farmaceutica
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
BRPI1015939A2 (pt) composição farmacêutica
EE201300005A (et) Ravimkoostis
BRPI0921654A2 (pt) formulação farmacêutica
DK2285413T3 (da) Farmaceutisk sammensætning
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
BR112012003258A2 (pt) Composição ativa de aroma
BRPI0921313A2 (pt) composição farmaucêutica
BRPI0912171A2 (pt) composição farmacêutica
BR112012003149A2 (pt) composição farmacêutica
BRPI0921301A2 (pt) composição farmacêutica
BRPI0912656A2 (pt) formulação farmacêutica sólida
BR112012029461A2 (pt) composição farmacêutica contendo solifenacina
EP2323984A4 (en) BIOACTIVE TWO-PHASE FORMULATIONS
IT1399492B1 (it) Composizioni farmaceutiche effervescenti contenenti n-acetilcisteina.
EP2488175A4 (en) PHARMACEUTICAL COMPOSITIONS